Cancer Navigation Strategy for Endocrine Therapy-Resistant Breast Tumors

Mitsuyoshi Nakao; Saori Fujiwara; Hirotaka Iwase

doi:10.1016/j.trecan.2018.04.005

Cancer Navigation Strategy for Endocrine Therapy-Resistant Breast Tumors

Trends Cancer. 2018 Jun;4(6):404-407. doi: 10.1016/j.trecan.2018.04.005. Epub 2018 May 19.

Authors

Mitsuyoshi Nakao¹, Saori Fujiwara², Hirotaka Iwase³

Affiliations

¹ Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto 860-0811, Japan. Electronic address: mitnakao@kumamoto-u.ac.jp.
² Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan; Hormone Action and Oncogenesis Section, Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
³ Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan.

PMID: 29860984
DOI: 10.1016/j.trecan.2018.04.005

Abstract

Estrogen receptor (ER) α-positive breast cancers frequently acquire resistance to endocrine therapy. However, recent studies found that a fraction of these tumors overexpress ER, and that estrogen treatment induces apoptosis. We propose a 'cancer navigation' strategy to systematically lead resistant cells to growth arrest and apoptosis.

Keywords: Breast cancer; ESR1 gene; endocrine resistance; estrogen receptor; estrogen-induced apoptosis.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents, Hormonal / pharmacology*
Apoptosis*
Breast Neoplasms / drug therapy
Breast Neoplasms / metabolism
Breast Neoplasms / pathology*
Cell Proliferation
Drug Resistance, Neoplasm*
Estrogen Receptor alpha / metabolism
Female
Humans
Signal Transduction

Substances

Antineoplastic Agents, Hormonal
Estrogen Receptor alpha